Rigel Pharmaceuticals, Inc. (RIGL) Hits Fresh High: Is There Still Room to Run?

Company Performance - Rigel Pharmaceuticals (RIGL) has seen a significant stock performance, with a 56.6% increase over the past month and a 77.2% gain since the start of the year, outperforming the Zacks Medical sector which is down 7.6% and the Zacks Medical - Drugs industry which has a 5.6% return [1] - The stock reached a new 52-week high of $30.43 in the previous session [1] Earnings and Valuation - Rigel has a strong record of positive earnings surprises, having beaten earnings consensus estimates in the last four quarters. In the latest earnings report on August 5, 2025, Rigel reported EPS of $3.28 against a consensus estimate of $1.97, exceeding revenue estimates by 28.99% [2] - The stock currently trades at 11.1X current fiscal year EPS estimates, below the peer industry average of 14.4X, and at 27.6X trailing cash flow compared to the peer group's average of 12.2X [5] Zacks Rank and Style Scores - Rigel holds a Zacks Rank of 2 (Buy) due to favorable earnings estimate revisions from analysts, meeting the criteria for potential further gains [6] - The company has a Value Score of B, Growth Score of A, and Momentum Score of A, resulting in a combined VGM Score of A [5] Industry Comparison - The Medical - Drugs industry is performing well, ranking in the top 35% of all industries, providing a favorable environment for both Rigel and its peer, Catalyst Pharmaceuticals, Inc. (CPRX) [9] - Catalyst Pharmaceuticals has a Zacks Rank of 2 (Buy) and has also shown strong earnings performance, beating consensus estimates by 17.24% [8]